Aptevo Secures $1.5M Grant for APVO451 Trispecific Solid Tumor Immunotherapy
APVO•Aptevo Therapeutics received a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to support IND-enabling preclinical studies for its trispecific antibody candidate APVO451 targeting nectin-4 in solid tumors. APVO451 is slated for development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027.
1. Grant Details
Aptevo Therapeutics received a $1.5 million non-dilutive research grant from the Andy Hill CARE Fund to fund IND-enabling preclinical studies for APVO451. The award validates the trispecific design and supports nectin-4-targeted immunotherapy development.
2. APVO451 Mechanism and Timeline
APVO451 combines nectin-4 targeting with CD40 and CD3 engagement in a single trispecific molecule to focus immune activation within solid tumors. The candidate is set for development candidate selection by year-end 2026 and IND-enabling studies in Q1 2027.
3. Strategic Pipeline Impact
APVO451 represents Aptevo’s strategic push into next-generation trispecific immunotherapies for solid tumors, building on its ADAPTIR platform. The grant accelerates the program’s progression and underscores the company’s commitment to precision immune-activation approaches.
